TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Stabilization of p53 in erythroid precursors in response to nucleosomal stress underlies the hypoplastic anemia in myelodysplastic syndromes (MDS) with chromosome 5q deletion [del(5q)]. We investigated whether cenersen, a clinically active 20-mer antisense oligonucleotide complementary to TP53 exon1...
| Автори: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
2013
|
| _version_ | 1826263485741268992 |
|---|---|
| author | Caceres, G McGraw, K Yip, B Pellagatti, A Johnson, J Zhang, L Liu, K Zhang, L Fulp, W Lee, J Al Ali, N Basiorka, A Smith, L Daugherty, F Littleton, N Wells, R Sokol, L Wei, S Komrokji, R Boultwood, J List, A |
| author_facet | Caceres, G McGraw, K Yip, B Pellagatti, A Johnson, J Zhang, L Liu, K Zhang, L Fulp, W Lee, J Al Ali, N Basiorka, A Smith, L Daugherty, F Littleton, N Wells, R Sokol, L Wei, S Komrokji, R Boultwood, J List, A |
| author_sort | Caceres, G |
| collection | OXFORD |
| description | Stabilization of p53 in erythroid precursors in response to nucleosomal stress underlies the hypoplastic anemia in myelodysplastic syndromes (MDS) with chromosome 5q deletion [del(5q)]. We investigated whether cenersen, a clinically active 20-mer antisense oligonucleotide complementary to TP53 exon10, could suppress p53 expression and restore erythropoiesis in del(5q) MDS. Cenersen treatment of ribosomal protein S-14-deficient erythroblasts significantly reduced cellular p53 and p53-up-regulated modulator of apoptosis expression compared with controls, accompanied by a significant reduction in apoptosis and increased cell proliferation. In a two-stage erythroid differentiation assay, cenersen significantly suppressed nuclear p53 in bone marrow CD34+ cells isolated from patients with del(5q) MDS, whereas erythroid burst recovery increased proportionally to the magnitude of p53 suppression without evidence of del(5q) clonal suppression (r = -0.6; P = 0.005). To explore the effect of p53 suppression on erythropoiesis in vivo, dexamethasone, a glucocorticoid receptor-dependent p53 antagonist, was added to lenalidomide treatment in eight lower-risk, transfusion-dependent, del(5q) MDS patients with acquired drug resistance. Transfusion independence was restored in five patients accompanied by expansion of erythroid precursors and decreased cellular p53 expression. We conclude that targeted suppression of p53 could support effective erythropoiesis in lenalidomide-resistant del(5q) MDS. |
| first_indexed | 2024-03-06T19:52:31Z |
| format | Journal article |
| id | oxford-uuid:246ea8a8-470f-4543-9b1a-da60e1dfea0b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:52:31Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:246ea8a8-470f-4543-9b1a-da60e1dfea0b2022-03-26T11:50:01ZTP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:246ea8a8-470f-4543-9b1a-da60e1dfea0bEnglishSymplectic Elements at Oxford2013Caceres, GMcGraw, KYip, BPellagatti, AJohnson, JZhang, LLiu, KZhang, LFulp, WLee, JAl Ali, NBasiorka, ASmith, LDaugherty, FLittleton, NWells, RSokol, LWei, SKomrokji, RBoultwood, JList, AStabilization of p53 in erythroid precursors in response to nucleosomal stress underlies the hypoplastic anemia in myelodysplastic syndromes (MDS) with chromosome 5q deletion [del(5q)]. We investigated whether cenersen, a clinically active 20-mer antisense oligonucleotide complementary to TP53 exon10, could suppress p53 expression and restore erythropoiesis in del(5q) MDS. Cenersen treatment of ribosomal protein S-14-deficient erythroblasts significantly reduced cellular p53 and p53-up-regulated modulator of apoptosis expression compared with controls, accompanied by a significant reduction in apoptosis and increased cell proliferation. In a two-stage erythroid differentiation assay, cenersen significantly suppressed nuclear p53 in bone marrow CD34+ cells isolated from patients with del(5q) MDS, whereas erythroid burst recovery increased proportionally to the magnitude of p53 suppression without evidence of del(5q) clonal suppression (r = -0.6; P = 0.005). To explore the effect of p53 suppression on erythropoiesis in vivo, dexamethasone, a glucocorticoid receptor-dependent p53 antagonist, was added to lenalidomide treatment in eight lower-risk, transfusion-dependent, del(5q) MDS patients with acquired drug resistance. Transfusion independence was restored in five patients accompanied by expansion of erythroid precursors and decreased cellular p53 expression. We conclude that targeted suppression of p53 could support effective erythropoiesis in lenalidomide-resistant del(5q) MDS. |
| spellingShingle | Caceres, G McGraw, K Yip, B Pellagatti, A Johnson, J Zhang, L Liu, K Zhang, L Fulp, W Lee, J Al Ali, N Basiorka, A Smith, L Daugherty, F Littleton, N Wells, R Sokol, L Wei, S Komrokji, R Boultwood, J List, A TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. |
| title | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. |
| title_full | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. |
| title_fullStr | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. |
| title_full_unstemmed | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. |
| title_short | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. |
| title_sort | tp53 suppression promotes erythropoiesis in del 5q mds suggesting a targeted therapeutic strategy in lenalidomide resistant patients |
| work_keys_str_mv | AT caceresg tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT mcgrawk tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT yipb tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT pellagattia tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT johnsonj tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT zhangl tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT liuk tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT zhangl tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT fulpw tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT leej tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT alalin tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT basiorkaa tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT smithl tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT daughertyf tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT littletonn tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT wellsr tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT sokoll tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT weis tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT komrokjir tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT boultwoodj tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients AT lista tp53suppressionpromoteserythropoiesisindel5qmdssuggestingatargetedtherapeuticstrategyinlenalidomideresistantpatients |